secwatch.observer — SEC 8-K summary
======================================

Issuer:     Black Diamond Therapeutics, Inc. (BDTX)
CIK:        0001701541
Form:       8-K
Filed at:   2024-06-06T23:59:59+00:00
Accession:  0001104659-24-069070
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Black Diamond Therapeutics shareholders approve officer liability limitation and elect directors
--------------------------------------------------------------------------------

- Shareholders approved Amendment to limit officer liability as permitted by Delaware law.
- Prakash Raman and Mark A. Velleca elected as Class I directors to serve until 2027.
- PricewaterhouseCoopers LLP ratified as independent auditor for FY2024.
- Certificate of Amendment filed and effective June 6, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701541/000110465924069070/0001104659-24-069070-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701541/000110465924069070/tm2416636d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-069070

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer